Glycoproteomics-based liquid biopsy: translational outlook for colorectal cancer clinical management in Southeast Asia

References

• 1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 14(10), 101174 (2021).
  MedlineGoogle Scholar
• 2. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 3. Hossain MS, Karuniawati H, Jairoun AA et al. Colorectal cancer: a review of carcinogenesis, global. Cancer 14(1732), 1–25 (2022).
  Google Scholar
• 4. UNESCAP. South-East Asia: demographic indicators. www.population-trends-asiapacific.org/data/sea
  Google Scholar
• 5. Ouakrim DA, Pizot C, Boniol M et al. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ 351, h4970 (2015).
  MedlineGoogle Scholar
• 6. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 21(20), 2525–2538 (2007).
  Medline CASGoogle Scholar
• 7. Wang H, Seow A, Lee HP. Trends in cancer incidence among Singapore Malays: a low-risk population. Ann. Med. Singapore 33(1), 57–62 (2004).
  MedlineGoogle Scholar
• 8. Hassan MRA, Ismail I, Suan MAM et al. Incidence and mortality rates of colorectal cancer in Malaysia. Epidemiol. Health 38, e2016007 (2016).
  MedlineGoogle Scholar
• 9. UNESCAP. Economic and social survey of Asia and the Pacific 2017: governance and fiscal management (2017). www.unescap.org/publications/economic-and-social-survey-asia-and-pacific-2017
  Google Scholar
• 10. Bailey CE, Hu C-Y, You YN et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 150(1), 17–22 (2015).
  MedlineGoogle Scholar
• 11. Mauri G, Vitiello PP, Sogari A et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br. J. Cancer 127(3), 394–407 (2022).
  Medline CASGoogle Scholar
• 12. Ding Y, Li W, Wang K, Xu C, Hao M, Ding L. Perspectives of the application of liquid biopsy in colorectal cancer. Biomed Res. Int. 2020, 6843180 (2020).
  MedlineGoogle Scholar
• 13. Marcuello M, Vymetalkova V, Neves RPL et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Aspects Med. 69, 107–122 (2019).
  Medline CASGoogle Scholar
• 14. Normanno N, Cervantes A, Ciardiello F, De Luca A, Pinto C. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev. 70, 1–8 (2018).
  Medline CASGoogle Scholar
• 15. Zhang W, Yang Z, Gao X, Wu Q. Advances in the discovery of novel biomarkers for cancer: spotlight on protein N-glycosylation. Biomark. Med. 14(11), 1031–1045 (2020).
  CASGoogle Scholar
• 16. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759–767 (1990).
  Medline CASGoogle Scholar
• 17. Smith G, Carey FA, Beattie J et al. Mutations in APC, Kirsten-ras, and p53 – alternative genetic pathways to colorectal cancer. Proc. Natl Acad. Sci. USA 99(14), 9433–9438 (2002).
  Medline CASGoogle Scholar
• 18. Rex DK, Sullivan AW, Perkins AJ, Vemulapalli KC. Colorectal polyp prevalence and aspirational detection targets determined using high definition colonoscopy and a high level detector in 2017. Dig. Liver Dis. 52(1), 72–78 (2020).
  MedlineGoogle Scholar
• 19. Corley DA, Jensen CD, Marks AR et al. Adenoma detection rate and risk of colorectal cancer and death. N. Engl. J. Med. 370(14), 1298–1306 (2014).
  Medline CASGoogle Scholar
• 20. Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J. Gastroenterol. 20(22), 6786 (2014).
  MedlineGoogle Scholar
• 21. Schliemann D, Paramasivam D, Dahlui M et al. Change in public awareness of colorectal cancer symptoms following the Be Cancer Alert Campaign in the multi-ethnic population of Malaysia. BMC Cancer 20(1), 1–12 (2020).
  Google Scholar
• 22. Hassan MRA, Khazim WKW, Mustapha NRN, Othman Z. National cancer patient registry-colorectal cancer in Malaysia. Ann. Oncol. 24, iv97 (2013).
  Google Scholar
• 23. Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70(3), 145–164 (2020).
  MedlineGoogle Scholar
• 24. Andrei P, Battuello P, Grasso G, Rovera E, Tesio N, Bardelli A. Integrated approaches for precision oncology in colorectal cancer: the more you know, the better. Semin. Cancer Biol. 84, 199–213 (2021).
  MedlineGoogle Scholar
• 25. American Cancer Society Cancer facts and statistics (2015). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html
  Google Scholar
• 26. Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5), 1570–1595 (2008).
  Medline CASGoogle Scholar
• 27. Simon K. Colorectal cancer development and advances in screening. Clin. Interv. Aging 11, 967 (2016).
  Medline CASGoogle Scholar
• 28. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med. 328(19), 1365–1371 (1993).
  Medline CASGoogle Scholar
• 29. Bailey JR, Aggarwal A, Imperiale TF. Colorectal cancer screening: stool DNA and other noninvasive modalities. Gut Liver 10(2), 204 (2016).
  Medline CASGoogle Scholar
• 30. Schreuders EH, Grobbee EJ, Spaander MCW, Kuipers EJ. Advances in fecal tests for colorectal cancer screening. Curr. Treat. Options Gastroenterol. 14(1), 152–162 (2016).
  MedlineGoogle Scholar
• 31. Dhaliwal A, Vlachostergios PJ, Oikonomou KG, Moshenyat Y. Fecal DNA testing for colorectal cancer screening: molecular targets and perspectives. World J. Gastrointest. Oncol. 7(10), 178 (2015).
  MedlineGoogle Scholar
• 32. Ebell MH. Accuracy of fecal DNA and fecal immunochemical test for colorectal cancer detection. Am. Fam. Physician 90(5), 326 (2014).
  Google Scholar
• 33. Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines 8(9), 308 (2020).
  Medline CASGoogle Scholar
• 34. Nakayama G, Tanaka C, Kodera Y. Current options for the diagnosis, staging and therapeutic management of colorectal cancer. Gastrointest. Tumors 1(1), 25–32 (2014).
  Google Scholar
• 35. Zauber AG, Winawer SJ, O’Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366, 687–696 (2012).
  Medline CASGoogle Scholar
• 36. De Wijkerslooth TR, Bossuyt PM, Dekker E. Strategies in screening for colon carcinoma. Neth. J. Med. 69(3), 112–119 (2011).
  MedlineGoogle Scholar
• 37. Baxter N, Rabeneck L. New findings about the risks and limitations of colonoscopy used in the early detection of colorectal cancer. Healthc. Q. 12(2), 24–25 (2009).
  MedlineGoogle Scholar
• 38. Cuyle P-J, Prenen H. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin. Belg. 72(2), 103–115 (2017).
  MedlineGoogle Scholar
• 39. Tournigand C, Andre T, Bonnetain F et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J. Clin. Oncol. 30(27), 3353–3360 (2012).
  Medline CASGoogle Scholar
• 40. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343–2351 (2004).
  Medline CASGoogle Scholar
• 41. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol. 29(11), 1465–1471 (2011).
  Medline CASGoogle Scholar
• 42. Yothers G, O’Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol. 29(28), 3768 (2011).
  Medline CASGoogle Scholar
• 43. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu. Rev. Med. 66, 83–95 (2015).
  Medline CASGoogle Scholar
• 44. Carethers JM. Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap. Adv. Gastroenterol. 1(1), 33–42 (2008).
  MedlineGoogle Scholar
• 45. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 134(5), 1296–1310 (2008).
  Medline CASGoogle Scholar
• 46. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370(14), 1287–1297 (2014).
  Medline CASGoogle Scholar
• 47. Inadomi JM, Vijan S, Janz NK et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch. Intern. Med. 172(7), 575–582 (2012).
  MedlineGoogle Scholar
• 48. Lone SN, Nisar S, Masoodi T et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer 21(1), 1–22 (2022).
  MedlineGoogle Scholar
• 49. Oshi M, Murthy V, Takahashi H et al. Urine as a source of liquid biopsy for cancer. Cancers (Basel). 13(11), 2652 (2021).
  Medline CASGoogle Scholar
• 50. Lim M, Kim C-J, Sunkara V, Kim M-H, Cho Y-K. Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA). Micromachines 9(3), 100 (2018).
  MedlineGoogle Scholar
• 51. Kudryavtseva AV, Lipatova AV, Zaretsky AR et al. Important molecular genetic markers of colorectal cancer. Oncotarget 7(33), 53959 (2016).
  MedlineGoogle Scholar
• 52. Watanabe T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Nagawa H. Microsatellite instability in adenoma as a possible marker to identify HNPCC patients. Am. J. Gastroenterol. 101(1), 204 (2006).
  MedlineGoogle Scholar
• 53. Ellegren H. Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet. 5(6), 435–445 (2004).
  Medline CASGoogle Scholar
• 54. Yamamoto H, Imai K. Microsatellite instability: an update. Arch. Toxicol. 89(6), 899–921 (2015).
  Medline CASGoogle Scholar
• 55. Setaffy L, Langner C. Microsatellite instability in colorectal cancer: clinicopathological significance. Polish J. Pathol. 66(3), 203–218 (2015).
  MedlineGoogle Scholar
• 56. Casak SJ, Marcus L, Fashoyin-Aje L et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin. Cancer Res. 27(17), 4680–4684 (2021).
  Medline CASGoogle Scholar
• 57. Aguiar-Ibáñez R, Hardern C, van Hees F et al. Cost–effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. J. Med. Econ. 25(1), 469–480 (2022).
  MedlineGoogle Scholar
• 58. Lofton-Day C, Model F, DeVos T et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2), 414–423 (2008).
  Medline CASGoogle Scholar
• 59. Han M, Liew CT, Zhang HW et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin. Cancer Res. 14(2), 455–460 (2008).
  Medline CASGoogle Scholar
• 60. Oh T, Kim N, Moon Y et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J. Mol. Diagnostics 15(4), 498–507 (2013).
  Medline CASGoogle Scholar
• 61. Thierry AR, Mouliere F, El Messaoudi S et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20(4), 430–435 (2014).
  Medline CASGoogle Scholar
• 62. Yen L-C, Yeh Y-S, Chen C-W et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin. Cancer Res. 15(13), 4508–4513 (2009).
  Medline CASGoogle Scholar
• 63. Habermann JK, Roblick UJ, Luke BT et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131(4), 1020–1029 (2006).
  Medline CASGoogle Scholar
• 64. Albrethsen J, Bøgebo R, Gammeltoft S, Olsen J, Winther B, Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 5(1), 1–10 (2005).
  MedlineGoogle Scholar
• 65. Lee H, Rhee H, Kang HJ et al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am. J. Clin. Pathol. 129(5), 772–779 (2008).
  MedlineGoogle Scholar
• 66. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Kedra B, Konopko M, Szmitkowski M. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin. Chim. Acta 371(1–2), 143–147 (2006).
  Medline CASGoogle Scholar
• 67. Yu J, Zhai X, Li X et al. Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci. Rep. 7(1), 1–10 (2017).
  MedlineGoogle Scholar
• 68. Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 5(1), 1–30 (2020).
  MedlineGoogle Scholar
• 69. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6(5), 479–491 (2016).
  Medline CASGoogle Scholar
• 70. Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. Semin. Cancer Biol. 84, 69–79 (2022).
  Medline CASGoogle Scholar
• 71. Dasari A, Morris VK, Allegra CJ et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol. 17(12), 757–770 (2020).
  MedlineGoogle Scholar
• 72. Batth IS, Mitra A, Manier S et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann. Oncol. 28(3), 468–477 (2017).
  Medline CASGoogle Scholar
• 73. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14(9), 531–548 (2017).
  Medline CASGoogle Scholar
• 74. Yu W, Hurley J, Roberts D et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann. Oncol. 32(4), 466–477 (2021).
  Medline CASGoogle Scholar
• 75. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845–856 (2005).
  Medline CASGoogle Scholar
• 76. Gutierrez-Reyes CD, Jiang P, Atashi M et al. Advances in mass spectrometry-based glycoproteomics: an update covering the period 2017–2021. Electrophoresis 43(1–2), 370–387 (2022).
  Medline CASGoogle Scholar
• 77. Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front. Oncol. 9(9), 380 (2019).
  MedlineGoogle Scholar
• 78. Hanzawa K, Tanaka-Okamoto M, Murakami H et al. Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients. PLOS ONE 17(4), e0266927 (2022).
  Medline CASGoogle Scholar
• 79. Azevedo R, Peixoto A, Gaiteiro C et al. Over forty years of bladder cancer glycobiology: where do glycans stand facing precision oncology? Oncotarget 8(53), 91734–91764 (2017).
  MedlineGoogle Scholar
• 80. Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat. Rev. Nephrol. 15(6), 346–366 (2019).
  MedlineGoogle Scholar
• 81. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22(6), 736–756 (2012).
  Medline CASGoogle Scholar
• 82. Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat. Rev. Mol. Cell Biol. 21(12), 729–749 (2020).
  Medline CASGoogle Scholar
• 83. Kailemia MJ, Park D, Lebrilla CB. Glycans and glycoproteins as specific biomarkers for cancer. Anal. Bioanal. Chem. 409, 395–410 (2017).
  Medline CASGoogle Scholar
• 84. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24(33), 5313–5327 (2006).
  Medline CASGoogle Scholar
• 85. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem. 47(4), 624–630 (2001).
  Medline CASGoogle Scholar
• 86. Xie H-L, Gong Y-Z, Kuang J-A, Gao F, Tang S-Y, Gan J-L. The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels. Cancer Manag. Res. 11, 7499 (2019).
  Medline CASGoogle Scholar
• 87. Ferreira JA, Magalhaes A, Gomes J et al. Protein glycosylation in gastric and colorectal cancers: toward cancer detection and targeted therapeutics. Cancer Lett. 387, 32–45 (2017).
  Medline CASGoogle Scholar
• 88. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15(9), 540–555 (2015).
  Medline CASGoogle Scholar
• 89. Mereiter S, Balmana M, Campos D, Gomes J, Reis CA. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell 36(1), 6–16 (2019).
  Medline CASGoogle Scholar
• 90. Marcos NT, Bennett EP, Gomes J et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front. Biosci. 3(4), 1443–1455 (2011).
  Google Scholar
• 91. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 63(4), 322–329 (2010).
  Medline CASGoogle Scholar
• 92. Fernandes E, Sores J, Cotton S et al. Esophageal, gastric and colorectal cancers: looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics 10(11), 4903–4928 (2020).
  Medline CASGoogle Scholar
• 93. Van’t Veer LJ, Dai H, Van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530–536 (2002).
  MedlineGoogle Scholar
• 94. Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF III, Liotta LA. Protein microarray detection strategies: focus on direct detection technologies. J. Immunol. Methods 290(1–2), 121–133 (2004).
  Medline CASGoogle Scholar
• 95. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5(10), 588–599 (2008).
  Medline CASGoogle Scholar
• 96. Abrahams JL, Taherzadeh G, Jarvas G, Guttman A, Zhou Y, Campbell MP. Recent advances in glycoinformatic platforms for glycomics and glycoproteomics. Curr. Opin. Struct. Biol. 62, 56–69 (2020).
  Medline CASGoogle Scholar
• 97. Ruhaak LR, Zauner G, Huhn C, Bruggink C, Deelder AM, Wuhrer M. Glycan labeling strategies and their use in identification and quantification. Anal. Bioanal. Chem. 397(8), 3457–3481 (2010).
  Medline CASGoogle Scholar
• 98. Kay Li Q, Gabrielson E, Zhang H. Application of glycoproteomics for the discovery of biomarkers in lung cancer. Proteomics Clin. Appl. 6(5–6), 244–256 (2012).
  MedlineGoogle Scholar
• 99. Engwegen JYMN, Helgason HH, Cats A et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 12(10), 1536 (2006).
  Medline CASGoogle Scholar
• 100. Mesri M. Advances in proteomic technologies and its contribution to the field of cancer. Adv. Med. 2014, 238045 (2014).
  MedlineGoogle Scholar
• 101. Mendes ML, Dittmar G. Targeted proteomics on its way to discovery. Proteomics 22(15–16), 2100330 (2022).
  CASGoogle Scholar
• 102. Riley NM, Bertozzi CR, Pitteri SJ. A pragmatic guide to enrichment strategies for mass spectrometry-based glycoproteomics. Mol. Cell. Proteomics 20, 100029 (2021).
  Medline CASGoogle Scholar
• 103. Shen F, Xiong Y, Zhang L et al. Rapid sample preparation workflow for serum sample analysis with different mass spectrometry acquisition strategies. Anal. Chem. 93(3), 1578–1585 (2020).
  MedlineGoogle Scholar
• 104. Shinozaki E, Tanabe K, Akiyoshi T et al. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer 18, 406 (2018).
  MedlineGoogle Scholar
• 105. Qiu Y, Patwa TH, Xu L et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 7(4), 1693–1703 (2008).
  Medline CASGoogle Scholar
• 106. Lindpaintner K, Desai K, Xu G et al. Identifying potential glycoproteomic biomarkers for diagnosis of colorectal cancer (CRC). J. Clin. Oncol. 40(Suppl. 16), e15529 (2022).
  Google Scholar
• 107. Wei H, Cheng Z, Ouyang C et al. Glycoprotein screening in colorectal cancer based on differentially expressed Tn antigen. Oncol. Rep. 36(3), 1313–1324 (2016).
  Medline CASGoogle Scholar
• 108. Gong Q, Zhang X, Liang A et al. Proteomic screening of potential N-glycoprotein biomarkers for colorectal cancer by TMT labeling combined with LC–MS/MS. Clin. Chim. Acta 521, 122–130 (2021).
  Medline CASGoogle Scholar
• 109. Lindpaintner K, Mitchell A, Pickering C et al. Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint inhibitor treatment benefit in metastatic malignant melanoma. J. Clin. Oncol. 40(Suppl. 16), 9545 (2022).
  Google Scholar
• 110. Mitchell A, Srinivasan A, Xu G et al. Predicting breast cancer in women using liquid biopsy-derived glycoproteomic markers. J. Clin. Oncol. 40(Suppl. 16), e12545 (2022).
  Google Scholar
• 111. Mitchell A, Pickering C, Xu G et al. Glycoproteomics as a powerful liquid biopsy-based screening tool for non-small cell lung cancer. J. Clin. Oncol. 40(Suppl. 16), e21148 (2022).
  Google Scholar
• 112. Serie D, Moser K, Pickering C et al. Liquid-biopsy-derived glycoproteomic profiling as a novel means for noninvasive diagnosis of ovarian cancer. J. Clin. Oncol. 40(Suppl. 16), e17604 (2022).
  Google Scholar
• 113. Serie D, Pickering C, Rice R et al. Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy. J. Clin. Oncol. 40(Suppl. 16), 11546 (2022).
  Google Scholar
• 114. Al-wajeeh AS, Ismail MN, Salhimi SM et al. Identification of glycobiomarker candidates for breast cancer using LTQ-Orbitrap fusion technique. Int. J. Pharmacol. 13(5), 425–437 (2017).
  CASGoogle Scholar
• 115. Wong Y-L, Anand R, Yuen KM et al. Identification of potential glycoprotein biomarkers in oral squamous cell carcinoma using sweet strategies. Glycoconj. J. 38(1), 1–11 (2021).
  Medline CASGoogle Scholar
• 116. Chokchaichamnankit D, Watcharatanyatip K, Subhasitanont P et al. Urinary biomarkers for the diagnosis of cervical cancer by quantitative label-free mass spectrometry analysis. Oncol. Lett. 17(6), 5453–5468 (2019).
  Medline CASGoogle Scholar
• 117. Boonyapranai K, Ounjaijean S, Kulprachakarn K et al. Haptoglobin polymorphisms and fucosylation change: possible influence of variation on the identified lung cancer-relevant biomarkers. Curr. Proteomics 18(3), 380–389 (2020).
  Google Scholar
• 118. Chantaraamporn J, Champattanachai V, Khongmanee A et al. Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer. Proteomes 8(3), 26 (2020).
  Medline CASGoogle Scholar
• 119. Ye Z, Vakhrushev SY. The role of data-independent acquisition for glycoproteomics. Mol. Cell Proteomics 20, 100042 (2021).
  Medline CASGoogle Scholar
• 120. Iqbal MJ, Javed Z, Sadia H et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell Int. 21(1), 270 (2021).
  MedlineGoogle Scholar
• 121. Nabirotchkin S, Peluffo AE, Rinaudo P, Yu J, Hajj R, Cohen D. Next-generation drug repurposing using human genetics and network biology. Curr. Opin. Pharmacol. 51, 78–92 (2020).
  Medline CASGoogle Scholar
• 122. Lindpaintner K. Glycoproteomics: a new era in biomarkers (2021). www.labnews.co.uk/article/2031446/glycoproteomics-a-new-era-in-biomarkers
  Google Scholar
• 123. Ginghina O, Hudita A, Zamfir M et al. Liquid biopsy and artificial intelligence as tools to detect signatures of colorectal malignancies: a modern approach in patient’s stratification. Front. Oncol. 12(March), 1–22 (2022).
  Google Scholar
• 124. Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput. Struct. Biotechnol. J. 18, 2300–2311 (2020).
  Medline CASGoogle Scholar
• 125. Wang Y, He X, Nie H, Zhou J, Cao P, Ou C. Application of artificial intelligence to the diagnosis and therapy of colorectal cancer. Am. J. Cancer Res. 10(11), 3575–3598 (2020).
  Medline CASGoogle Scholar
• 126. Kasi PM, Shen L, Ramachandran P et al. Serum glycoproteomic-based liquid biopsy for the detection of pancreatic ductal adenocarcinoma. J. Clin. Oncol. 38(Suppl. 4), 763 (2020).
  Google Scholar
• 127. Lindpaintner K, Cheng M, Prendergast J et al. Blood-based glycoprotien signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade. J. Immunother. Cancer 9(Suppl. 2), A35 (2021).
  Google Scholar
• 128. Ramachandran P, Xu G, Huang HH et al. Serum glycoprotein markers in nonalcoholic steatohepatitis and hepatocellular carcinoma. J. Proteome Res. 21(4), 1083–1094 (2022).
  Medline CASGoogle Scholar
• 129. Pickering C, Zhou B, Xu G et al. Differential peripheral blood glycoprotein profiles in symptomatic and asymptomatic COVID-19. Viruses 14(3), 553 (2022).
  Medline CASGoogle Scholar
• 130. Mitsala A, Tsalikidis C, Pitiakoudis M, Simopoulos C, Tsaroucha AK. Artificial intelligence in colorectal cancer screening, diagnosis and treatment. A new era. Curr. Oncol. 28(3), 1581–1607 (2021).
  MedlineGoogle Scholar
• 131. Zhou H, Zhu L, Song J et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol. Cancer 21(1), 86 (2022).
  Medline CASGoogle Scholar
• 132. Taghiakbari M, Mori Y, von Renteln D. Artificial intelligence-assisted colonoscopy: a review of current state of practice and research. World J. Gastroenterol. 27(47), 8103 (2021).
  MedlineGoogle Scholar
• 133. Wang W, Yin Y, Shan X et al. The value of plasma-based microRNAs as diagnostic biomarkers for ovarian cancer. Am. J. Med. Sci. 358(4), 256–267 (2019).
  MedlineGoogle Scholar
• 134. Chen H, Zhou Q. Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease. Oncol. Rep. 49(5), 1–13 (2023).
  MedlineGoogle Scholar
• 135. Almeida A, Kolarich D. The promise of protein glycosylation for personalised medicine. Biochim. Biophys. Acta 1860(8), 1583–1595 (2016).
  Medline CASGoogle Scholar
• 136. Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev. Proteomics 1(1), 49–55 (2004).
  Medline CASGoogle Scholar
• 137. Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR. Artificial intelligence applications in inflammatory bowel disease: emerging technologies and future directions. World J. Gastroenterol. 27(17), 1920 (2021).
  Medline CASGoogle Scholar
• 138. Liu Y, Zhang C, Wang Q et al. Global, regional, and national burden of colorectal cancer and attributable risk factors, from 1990 to 2019: updated results from the Global Burden of Disease Study 2019. Res. Square 7(7), 627–647 (2022).
  Google Scholar
• 139. Soon S, Chia JW, Chew MH, Tan WS, Yang XY, Wee HL. Gender-specific patterns of productivity loss in colorectal cancer survivors in a multi-ethnic Asian population. Value Health 19(7), A807 (2016).
  Google Scholar
• 140. WHO. Cardiovascular diseases, diabetes and cancer cost nearly RM 9 billion productivity losses annually to Malaysian economy (2020). www.who.int/malaysia/news/detail/08-09-2020-cardiovascular-diseases-diabetes-and-cancer-cost-nearly-rm-9-billion-productivity-losses-annually-to-malaysian-economy
  Google Scholar
• 141. Kong Y-C, Sakti V-V, Sullivan R, Bhoo-Pathy N. Cancer and COVID-19: economic impact on households in southeast Asia. Ecancermedicalscience 14, 1134 (2020).
  MedlineGoogle Scholar
• 142. Azzani M, Dahlui M, Ishak WZW, Roslani AC, Su TT. Provider costs of treating colorectal cancer in government hospital of Malaysia. Malaysian J. Med. Sci. 26(1), 73 (2019).
  Google Scholar
• 143. Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR et al. Productivity savings from colorectal cancer prevention and control strategies. Am. J. Prev. Med. 41(2), e5–e14 (2011).
  MedlineGoogle Scholar
• 144. Heavener T, McStay FW, Jaeger V et al. Assessing adherence and cost-benefit of colorectal cancer screening for accountable providers. Presented at: Baylor University Medical Center Proceedings. Taylor & Francis. 32(4), 490–497 (2019).
  Google Scholar
• 145. van Ballegooijen M, Habbema JDF, Boer R et al. Acomparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. (2015).
  Google Scholar
• 146. UKM. Colorectal Cancer Screening | The Malaysian Cohort. https://www.ukm.my/mycohort/ms/colorectal-cancer-screening/
  Google Scholar
• 147. Cologuard® Cost | Cologuard Patient Site. https://www.cologuard.com/affordable
  Google Scholar
• 148. Guardant Health, Inc. Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360R CDx Test. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Receives-ADLT-Status-from-CMS-for-FDA-Approved-Guardant360-CDx-Test/default.aspx
  Google Scholar
• 149. Karol D, McKinnon M, Mukhtar L et al. The impact of foundation medicine testing on cancer patients: A single academic centre experience. Front. Oncol. 11, 687730 (2021).
  MedlineGoogle Scholar
• 150. Young PE, Womeldorph CM. Colonoscopy for colorectal cancer screening. J. Cancer 4(3), 217–226 (2013).
  MedlineGoogle Scholar
• 151. Osborne JM, Wilson C, Moore V, Gregory T, Flight I, Young GP. Sample preference for colorectal cancer screening tests: blood or stool? Open J. Prev. Med. 2(3), 326–331 (2012).
  Google Scholar
• 152. Precedence Research. Liquid Biopsy Market Size to Hit US$ 26.2 Billion by 2030 (2021). www.globenewswire.com/en/news-release/2021/12/14/2351913/0/en/Liquid-Biopsy-Market-Size-to-Hit-US-26-2-Billion-by-2030.html
  Google Scholar
• 153. Timothy G. ‘Singapore medical company invents non-invasive cancer screening tests; receives US$20m in funding | The Straits Times’ (2019). www.straitstimes.com/singapore/health/singapore-medical-company-invents-non-invasive-cancer-screening-tests-receives
  Google Scholar
• 154. Mazouji O, Ouhajjou A, Incitti R, Mansour H. Updates on clinical use of liquid biopsy in colorectal cancer screening, diagnosis, follow-up, and treatment guidance. Front. Cell Dev. Biol. 9(May), 660924 (2021).
  MedlineGoogle Scholar
• 155. Bakker E, Hendrikse NM, Ehmann F et al. Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020. Clin. Pharmacol. Ther. 112(1), 69–80 (2022).
  MedlineGoogle Scholar
• 156. Food and Drug Administration. HHS. International conference on harmonisation; guidance on e16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions; availability. Notice. Federal register 76(155), 49773–49774 (2011).
  MedlineGoogle Scholar
• 157. Menetski JP, Hoffmann SC, Cush SS et al. The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction. Clin. Pharmacol. Ther. 105(4), 829–843 (2019).
  MedlineGoogle Scholar
• 158. See HY, Mohamed MS, Nor SNM, Low WY. Challenges in the ethical review of clinical and biomedical research in Malaysia: a mixed methods study. J. Empir. Res. Hum. Res. Ethics 16(5), 487–500 (2021).
  MedlineGoogle Scholar
• 159. Glasziou P, Scott AM, Chalmers I, Kolstoe SE, Davies HT. Improving research ethics review and governance can improve human health. J. R. Soc. Med. 114(12), 556–562 (2021).
  MedlineGoogle Scholar
• 160. Universiti Kebangsaan Malaysia. BIOBANK | UKM Medical Molecular Biology Institute (2022). www.ukm.my/umbi/?s=BIOBANK
  Google Scholar
• 161. Zain RB, Athirajan V, Ghani WMN et al. An oral cancer biobank initiative: a platform for multidisciplinary research in a developing country. Cell Tissue Bank. 14(1), 45–52 (2013).
  Medline CASGoogle Scholar
• 162. Baláž V, Jeck T, Balog M. Economics of biobanking: business or public good? Literature review, structural and thematic analysis. Soc. Sci. 11(7), 288 (2022).
  Google Scholar
• 163. Chong HY, Allotey PA, Chaiyakunapruk N. Current landscape of personalized medicine adoption and implementation in southeast Asia. BMC Med. Genomics 11(1), 1–15 (2018).
  Medline CASGoogle Scholar